The Effect of Pharmaceutical Grade L-glutamine (Endari) on Glycemic Control in Patients With Diabetes Mellitus Type II

• Status: Not yet recruiting
• Trial end date: 2022-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is an initial non-blinded, non-placebo controlled trial to determine the efficacy of L-glutamine in lowering blood sugar in patients with diabetes mellitus type II without sickle cell anemia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hawaii Pacific Health

Criteria

Inclusion Criteria:

• Confirmed diagnosis of diabetes mellitus type II

• Patient of Straub Medical Center, Internal Medicine Clinic

Exclusion Criteria:

• Renal and liver impairment ( GFR less than 40)

• Transaminitis (elevation of AST of ALT more than 2 fold)

• Patient with sickle cell anemia